Skip to main content
Premium Trial:

Request an Annual Quote

DVS Sciences Collaborating with Cytobank on Informatics Tools for CyTOF Platform

Premium

DVS Sciences, developer of the CyTOF mass cytometry platform, this week announced a business agreement with flow cytometry informatics firm Cytobank to develop a cloud-based informatics platform for managing and analyzing CyTOF data.

Named DVS Cytobank, the platform will be released to early-access customers in August with a wide commercial release planned for November. Financial and other details of the agreement were not disclosed.

Combining capabilities of flow cytometry and atomic mass spectrometry, the CyTOF is able to simultaneously quantify as many as 100 protein biomarkers in individual cells at a rate of roughly 1,000 cells per second.

These capabilities make it a potentially valuable tool for large-scale proteomic studies, such as one published in Science last year by Stanford University researcher Garry Nolan (PM 5/13/2011). It also creates a need for informatics tools capable of processing and analyzing such massive quantities of data.

“The marriage of uniquely informative data acquired by our CyTOF instruments and reagents with the powerful capabilities of the Cytobank cloud-based platform will be enabling for our researchers around the world as they analyze, manage, and share large amounts of multi-parameter data,” Joseph Victor, president and CEO of DVS, said in a statement.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.